drugset / Trial / NCT03169231
Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a randomized, placebo-controlled, double-blind, parallel arm, multi-center Phase 2b study.
Timeline
- Start
- 2017-07-06
- Primary completion
- 2021-09-30
- Completion
- 2021-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mesenchymal stem cell | Cell therapy | 25 cells | Intravenous |
| Subject | Mesenchymal stem cell | Cell therapy | 50 cells | Intravenous |
| Subject | Mesenchymal stem cell | Cell therapy | 100 cells | Intravenous |
| Subject | Mesenchymal stem cell | Cell therapy | 200 cells | Intravenous |
Indications
No indication recorded.